Next-Gen Cell Target Engagement
Our Webinars
Real-Time Cellular Target Engagement - Part 2
This webinar provides a deep journey into real-time applications of MICRO-TAG Cell Target Engagement, specifically tuned for challenging drug targets.
Challenging drug targets require the complexities of the cellular environment for proper folding and function. MICRO-TAG cell target engagement technology improves on the existing methods by integrating enzyme complementation for fluorescence development, supporting superior signal-to-noise ratios, and enabling improved sensitivity and dynamic range by pairing with real-time systems, such as an Applied Biosystems QuantStudio™ instrument for real-time detection of cell target engagement.
Real-Time Cellular Target Engagement - Part 1
Cellular drug–target engagement enables validation and analysis of direct drug–target interactions in the context of living cells. However, for challenging drug targets, the bar is further raised since these targets heavily depend on the cellular milieu and transient proteomic interactions for contextual folding and function. MICRO-TAG cell target engagement technology improves on the existing methods by integrating enzyme complementation for fluorescence development, supporting better signal-to-noise ratios, and enabling improved sensitivity and dynamic range by pairing with real-time systems, such as an Applied Biosystems QuantStudio™ instrument for real-time detection of cell target engagement.
Discovery of Novel DHFR Inhibitors
The webinar reviews the story of discovery of novel human DHFR inhibitors, presented by Professor Dennis Wright of University of Connecticut. UCP1162 is a structurally novel anti-folate that can evade cellular resistance. UCP1162 inhibits the human DHFR with affinity and kinetics comparable to methotrexate (MTX) and demonstrated promising mechanistic properties in reducing acute inflammation. We likewise demonstrate the pivotal role Micro-Tag™ cell target engagement played in discovery of novel DHFR Inhibitors.
Novel Druggable Targets - Inhibitors of TBL1 from Discovery to Clinic
Stephen Horrigan PhD, CSO @ Iterion Therapeutics, a clinical-stage biotech company, is reviewing the drug discovery story of inhibitors for TBL1 (Transducin beta-like protein 1). TBL1 is a high-value challenging therapeutic target involved in a number of essential cellular functions. Stephen is dissecting the TBL1 story from discovery to clinic. Elmar Nurmemmedov PhD, Cofounder @ CellarisBio, is covering the importance of Micro-Tag™ cell target engagement technology in de-risking and accelerating the TBL1 program.
Predictive Drug Discovery Empowered with Cell Target Engagement
Here we bring together the two major elements in early drug discovery: Target engagement in silico & Target engagement in cell.
Eric Sigel, CEO @ Citadel Discovery, we will dissect the fundamentals of predictive drug discovery and DEL / ML to fuel therapeutic pipelines focused on challenging drug targets. Ivan Babic, Cofounder @ CellarisBio, will dissect the importance of pairing predictive drug discovery with live cell systems.
Target Engagement in Early Drug Discovery
This webinar provides insight into practices of target discovery & validation together with importance of target engagement in designing winning drug discovery programs. Starred by Dr Christopher Miller, ex-head genomics research center at Abbvie and ex-VP of functional genomics at GSK, we dissect the success of target discovery and validation through functional genomics. Dr Miller also ties into the importance of target engagement early in drug discovery.
Discovery of Pan-KRAS Inhibitors with Robust Anti-Tumor Activity
In this webinar we review the discovery of potent pan-KRAS inhibitors for gastrointestinal and pancreatic cancers. Led by legendary Professor Gary A. Piazza of Auburn University, the story will delve into layers of target biology, mechanism of action of the novel KRAS inhibitors, together with the preclinical data.
Paradigm of Cell Target Engagement
The webinar will review the fundamentals of cell target engagement and its importance in early drug discovery. It provides a short comparative synopsis of conventional biophysical methods (such as SPR, MST, DSF etc) that require purified and well structured and functional recombinant proteins. It also provides a review of cell target engagement methods together with enzyme complementation technologies.
Our BloG
Copyright © 2025 CellarisBio - All Rights Reserved.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.